Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer

Ryan M. Tierney, Matthew A. Powell, David G. Mutch, Randall K. Gibb, Janet S. Rader, Perry W. Grigsby

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Purpose. The aim of this study was to determine the acute toxicity of postoperative intensity-modulated radiotherapy (IMRT) with and without chemotherapy in patients with endometrial cancer. Materials and methods. A total of 19 patients with stages IB-IVB endometrial cancer who underwent surgery and postoperative IMRT were reviewed. The treatment planning goal was to cover the tissue at risk and minimize the dose to the bladder, bowel, and bone marrow. Median dose was 50.4 Gy (range 49.6-51.2 Gy). Altogether, 14 patients underwent chemotherapy; most were given carboplatin and paclitaxel. Toxicity was scored according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Results. The prescribed radiation treatment was completed in all patients. The prescribed cycles of chemotherapy were completed in all 14 patients, except one who received five of six cycles limited by prolonged thrombocytopenia. Chemotherapy was delayed in two patients (14%). Three patients required growth factor support during chemotherapy, and one patient required a blood transfusion. Acute grades 3-4 hematological toxicity occurred in 9 of the 14 patients (64%) who underwent chemotherapy. None experienced acute grade 3 or 4 genitourinary or gastrointestinal toxicity. Conclusion. Adjuvant IMRT and chemotherapy following surgery in patients with endometrial cancer is well tolerated and did not lead to treatment modification in most patients.

Original languageEnglish
Pages (from-to)439-445
Number of pages7
JournalRadiation Medicine - Medical Imaging and Radiation Oncology
Issue number9
StatePublished - Nov 2007


  • Chemotherapy
  • Endometrial cancer
  • IMRT
  • Toxicity


Dive into the research topics of 'Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer'. Together they form a unique fingerprint.

Cite this